Press Releases

 

 

Press Releases

DateNews
Nov. 3, 2021SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS
Oct. 6, 2021Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
Aug. 12, 2021SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN
Jul. 27, 2021Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
Jul. 20, 2021SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL
Jul. 8, 2021Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
Jun. 9, 2021SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED
May. 25, 2021SUNSHINE BIOPHARMA’S Adva-27a DESTROYS CANCER CELLS EXPRESSING P-GLYCOPROTEIN, A MARKER PRESENT IN OVER 50% OF ALL CANCER TYPES
May. 20, 2021SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING
May. 13, 2021SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING
May. 4, 2021SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION
Apr. 22, 2021RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA
Apr. 19, 2021SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT
Mar. 23, 2021SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT
Mar. 11, 2021SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN EUROPE UNTIL 2033
Mar. 4, 2021Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a And Initiates QA/QC Testing
Mar. 1, 2021Sunshine Biopharma Launches Online Store for Its Science-Based Nutritional Supplements
Feb. 18, 2021Sunshine Biopharma Discusses The Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast
Feb. 10, 2021SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY
Feb. 4, 2021SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS
Feb. 2, 2021SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033
Jan. 27, 2021SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB
Jan. 14, 2021SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Dec. 22, 2020SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK
Dec. 8, 2020SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS
Dec. 3, 2020SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET
Dec. 1, 2020SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 plus FINANCING FOR CORONAVIRUS TREATMENT
Nov. 24, 2020SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY
Nov. 18, 2020Sunshine Biopharma Signs An Agreement With A Montreal-Based Company To Advance The Development Of Adva-27a Anticancer Compound
Nov. 10, 2020Sunshine Biopharma Signs an Agreement for Distribution of Essential-9TM in Asia and the Far East
Oct. 26, 2020SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Oct. 19, 2020SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG
Oct. 7, 2020SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND
Sep. 15, 2020SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT
Aug. 25, 2020SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE
Jun. 3, 2020SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT
Nov. 6, 2019SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT
Oct. 17, 2019SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER
Sep. 3, 2019Sunshine Biopharma Receives Vegan Certification for Essential 9™ Amino Acids Supplement
May 28, 2019In Addition to Essential 9™, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca
May 16, 2019Sunshine Biopharma Announces that Essential 9™ is Now Available in the United States on Amazon.com
Mar. 12, 2019SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA
Feb. 4, 2019Sunshine Biopharma Receives Notice Of Allowance For A New Patent Application Extending Protection Of Adva-27a Anticancer Drug Until 2033
Dec. 17, 2018Sunshine Biopharma Receives Health Canada Approval for Essential 9™, The Company’s First Over The Counter Essential Micronutrient
Dec. 12, 2018Sunshine Biopharma Signs an Agreement With Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug
Sep. 14, 2018Sunshine Biopharma Announces $10 Million Equity Financing
Aug. 16, 2018Sunshine Biopharma Signs A Service Agreement With Utah Based Quintessential Biosciences Inc.
Jun. 18, 2018Sunshine Biopharma Launches Microbiology Testing Service
May 10, 2018Sunshine Biopharma Annouces Extension Of The Term Of Its Brokered Up To $10 Million Private Placement Financing
Jan. 4, 2018Sunshine Biopharma Completes the Acquisition of Atlas Pharma
Sep. 5, 2017Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million For Clinical Trials Of Adva-27a Anticancer Drug
Jun. 26, 2017Sunshine Biopharma Releases Results of Independent Valuation
Jun. 19, 2017Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License
Jan. 11, 2017Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing
Dec. 9, 2016Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma
Jun. 30, 2016Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
May 11, 2016Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company’s First Generic Drug For Treatment Of Breast Cancer
Mar. 15, 2016Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound
Jan. 20, 2016Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
Dec. 28, 2015Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
Oct. 9, 2015Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a
Aug. 4, 2015Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials
May 26, 2015Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland
Mar. 24, 2015Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
Feb. 25, 2015Sunshine Biopharma Announces Change To Its Board Of Directors And Officers
Nov. 19, 2014Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a
Nov. 3, 2014Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a
Oct. 14, 2014Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations
Oct. 1, 2014Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License
Sep. 3, 2014Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound
Aug. 21, 2014Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical Establishment License
Aug. 11, 2014Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations
Jun. 9, 2014Sunshine Biopharma’s Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
May 12, 2014Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
Apr. 29, 2014Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
Apr. 7, 2014Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro
Mar. 31, 2014Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise
Feb. 14, 2014Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a As A Treatment For This Deadly Form Of Cancer
Jun. 19, 2013Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling
Jun. 4, 2013Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
May 1, 2013Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers
Apr. 9, 2013Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
Mar. 14, 2013Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant Breast Cancer Drug, Adva-27a
Feb. 26, 2013Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a
Jan. 15, 2013Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a Anticancer Compound
Dec. 10, 2012Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells
Dec. 4, 2012Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a
Nov. 27, 2012Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
Nov. 13, 2012Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
Oct. 9, 2012Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a
Sep. 25, 2012Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in Oct. Issue of ANTICANCER RESEARCH
Sep. 20, 2012Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials
Sep. 13, 2012Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a
Sep. 4, 2012Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound’s Anti-Cancer Activity
Aug. 15, 2012Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
Aug. 3, 2012BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report
Jul. 30, 3012Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
Jul. 24, 2012Biotech Investor Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a
Jul. 11, 2012Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a
Jul. 9, 2012Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
Jul. 2, 2012Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound – Adva-27a for Aggressive Forms of Cancer
Jun. 26, 2012Sunshine Biopharma’s Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
May 22, 2012Pharmacokinetics Parameters of Sunshine Biopharma’s Lead Anti-Cancer Compound Exceed Expectations>
Apr. 9, 2012Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
Mar. 26, 2012Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago
Nov. 28, 2011Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals
Nov. 15, 2011Sunshine Biopharma’s Announces Successful Completion of Preclinical Studies for Adva-27a, The Company’s Lead Anti-Cancer Compound
Oct. 5, 2011Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor
Aug. 30, 2011Clearance of Sunshine Biopharma’s Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
Jul. 27, 2011Sunshine Biopharma Looking to Mimic Roche’s Billion Dollar Cancer Drug Success
Jul. 25, 2011Sunshine Biopharma’s Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
Jul. 11, 2011Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
Jun. 27, 2011Sunshine Biopharma’s Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
Jun. 17, 2011Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
Apr. 1, 2011Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com
Mar. 4, 2011CEO CFO Interviews Dr. Steve N. Slilaty
Feb. 25, 2011Interview with Central NY Business Journal
Jan. 26, 2011FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1
Jan. 21, 2011Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement
Oct. 26, 2010CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.
Oct. 13, 2010Sunshine Biopharma, Inc. Begins Drug Development Activities
Oct. 20, 2009Mountain West Business Solutions Acquires Sunshine Biopharma